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ABSTRACT
Metastatic cascade in malignant tumors, including breast cancer, starts with localized invasion of the 
host tissue. This process, requiring that tumor cells separate from each other, includes loss of homo-
typic and heterotypic cell adhesion and cell-cell contact inhibition, acquisition of motility, exacerbated 
by “epithelial-to-mesenchymal transition”, and production of proteolytic enzymes which degrade basal 
membrane and extracellular matrix. In this sense, aside from urokinase type plasminogen activator, 
increased expression and activity of matrix metalloproteinases (MMPs) is one of the earliest and most 
sustained events in tumor progression, playing a role in angiogenesis, invasion and metastasis. MMPs 
are a family of 23 zinc metalloproteinases, secreted as latent pro-enzymes, activated by proteolytic 
cleavage, and inhibited by the tissue inhibitors of metalloproteinases. The most commonly connected 
MMPs with the processes of metastasis are MMP-2 (gelatinase A) and MMP-9 (gelatinase B), due to 
their ability to degrade collagen type IV, major component of vascular basement membrane. MMP-2 and 
MMP-9 are also required for the switch to the “angiogenic phenotype” during tumor progression and 
activation of dormant tumor cells. The association of the increase in serum MMP-2 and MMP-9 activity 
and clinical stage suggests the usefulness of these parameters as markers in the follow-up and progno-
sis of breast cancer patients. The concept of “stromal-directed therapy” of cancer, with MMP- inhibitors 
directed against MMPs as targets, is based on the observed MMP up-regulation in tumors.
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INTRODUCTION
M
MPs are a family of structurally related zinc-dependent endopeptidases that are 
engaged, aside from various physiological processes such as embryogenesis, 
reproduction, uterine involution, angiogenesis, in pathological conditions, such as tumor 
invasion,  by mediating degradation of basement membrane and remodeling of extracel-
lular matrix. As invasiveness and metastasis are important biological characteristics of 
malignant tumors, these processes are extensively investigated and it has been shown 
that increased expression and activity of MMPs are among the earliest and most sustained 
events in tumor progression.
It has been established that the first stage of metastatic cascade involves the localized 
invasion of the host tissue. In order for this to happen, tumor cells must separate from 
each other, overcoming the usual restrictions imposed by homotypic cell adhesion and 
cell-cell contact inhibition. Normal cells are connected with each other and the surrounding 
stroma by different adhesive molecules. Endothelial cadherins (E-cadherins) represent the 
best-characterized molecular marker expressed in epithelial cells (1). They are a family of 
transmembrane glycoproteins, molecules engaged in connection between endothelial cells 
and the surrounding stroma thus maintaining the architectural structure of epithelial tissues.   
Whereas the extracellular domain of E-cadherin mediates calcium-dependent homotypic 
interaction with E-cadherin molecules on adjacent endothelial cells, the intracellular domain 
binds cytosolic catenins and provides a link to the actin cytoskeleton (2). 
Therefore, in many carcinomas  the loss of E-cadherin expression correlates with an invasive 
and undifferentiated phenotype. Furthermore, the normal function of E-cadherins depends on 
their association with catenins. The loss of adhesive E-cadherin molecules and  the E-cadherin 
– catenin complexes leads, morphologically, into impaired structure of the cytoskeleton and 
allows ameboid movement and motility, but also deregulates the cell cycle and leads to cell 
proliferation. The observed decrease in adhesive force facilitates dispersion of carcinoma cells 
from the primary tumor mass. In addition to promoting passive dissemination of carcinoma 
cells, loss of E-cadherin function can also promote cell invasiveness (3). 
Aside from these, there is yet another mechanism to alter E-cadherin function, its proteolytic 
modification. E-cadherin function can be disrupted by degradation of E-cadherin’s extracel-
lular domains by stromelysin-1 (MMP-13), a member of MMP-family that has been closely 
linked with tumor progression (4). Constitutive expression of active stromelysin in mammary 
epithelial cells results in cleavage of E-cadherin and progressive phenotypic changes in 
vitro, including loss of catenins from cell-cell contacts, down-regulation of cytokeratins, and 
up-regulation of vimentin and MMP-9. These changes result in a stable epithelial to mesen-
chymal transition of cellular phenotype. In vivo stromelysin expression promotes mammary 
carcinogenesis that includes certain genomic changes (5). Thus, a decrease in cell-cell 
adhesion is associated with malignant conversion. Forced expression of E-cadherin in tumor 
cell lines results in reversion from an invasive to a benign tumor cell phenotype (1,2). 
For most carcinomas, progression toward malignancy is accompanied by loss of epithelial 
differentiation and a shift towards a mesenchymal phenotype. This process, referred to 
as epithelial-to-mesenchymal transition (EMT), exacerbates motility and invasiveness of 
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many cell types and it is considered as a crucial event in late stage tumorigenesis and a 
prerequisite for tumor infiltration and metastasis (6). EMT provides mechanisms for epithe-
lial cells to overcome the physical constraints imposed on them by intercellular junctions 
and adopt a motile phenotype. The transition from a well-differentiated epithelial phenotype 
to an invasive mesenchymal phenotype may involve diverse molecular mechanisms that 
may independently enhance motility and invasiveness. EMT is characterized by proteolytic 
loss of E-cadherin or Endothelial - to Neural-cadherin (N-cadherin) “switching” and by 
increasing motility plays a crucial role during invasion and metastasis of carcinomas (3). 
Mesenchymal cells in the absence of tight junctions, lack an apical-basolateral polarity. 
Instead, these cells possess an elongated morphology with front-back asymmetry that 
facilitates motility and locomotion. Filopodial extensions at the leading edge of the mesen-
chymal cells are enriched with integrin family receptors that interact with the ECM and also 
contain MMPs that digest basement membranes and promote invasion. 
Transforming growth factor (TGF)-beta plays a pivotal role in inducing EMT of various 
epithelial cell types. Proteins upregulated during EMT, including Src kinase, integrin-linked 
kinase, integrin h-5, and MMP-11, MMP-12, and MMP-14, induce cytoskeletal remodeling 
and promote cell motility (7). The plasticity of malignant carcinoma cells due to diverse 
molecular mechanisms that contribute to EMT, also allows incomplete EMT, reversion to an 
epithelial phenotype and collective migration. As these mechanisms can manifest in a series 
of independent and reversible steps, EMT represents just one mechanism in the global 
metastatic carcinoma development process (8,9). Loss of p53 allows an upregulation of 
MMP-2 and downregulation of E-cadherin modulation of Slug and regulation of cancer cell 
invasion and metastasis (10,11).
The additional loss of heterotypic adhesion of endothelial cells, maintained by B1 and B2
integrins (e.g. VLA-1), as receptors for different components of ECM, BM, a highly special-
ized layer of the extracellular matrix composed of dense, intertwined fibrils of collagen 
type IV and glycoproteins, such as laminin and heparan sulfate proteoglycan, as well as 
similar components in the extracellular matrix (ECM), also allow detachment and invasion. 
A fundamental difference of neoplastic cells is the loss of anchorage requirement for cell 
survival and growth. The anchorage-independent growth of tumor cells may result from an 
uncoupling of cell survival signals transduced from the ECM by attachment, coupled with 
activation of cell-cycle progression is associated with neoplastic transformation (12).
TWO PROTEOLYTIC SYSTEMS
In the process of degradation of surrounding stroma tumor cells use two proteolytic systems. It 
has been proposed that a cascade of degradative enzymes clears a path at the advancing edges 
of invasive tumors, through which the tumor cells move. The inactive, pro-enzyme forms of the 
degradative enzymes (zymogens) are locally secreted, and become active by the action of their 
regulatory enzymes which are produced either by the tumor cells themselves or the surrounding 
stromal cells (fibroblasts, mast cells). Such zymogens include pro-cathepsins, plasminogens and 
procollagenases, heparanases and matrix metalloproteinases (MMPs). Of these the best charac-
terized in the process of invasion are MMPs and plasminogen activation system (13,14).
Plasminogen activation is an extracellular proteolytic system, which has been well char-
acterized at the molecular level. Plasminogen activator molecules convert the inactive 
plasminogen into a trypsin-like serine protease plasmin. Plasmin has a very broad substrate 
specificity and can degrade matrix proteins and can convert other zymogens (i.e. MMPs) to 
their active forms by proteolysis. Two plasminogen activators have been defined, urokinase 
plasminogen activator (uPA) and tissue-type PA (tPA) (15). It has been shown that uPA 
is essential in cell migration and invasion. Therefore, manipulation with the levels of uPA 
activity can modulate tumor invasiveness and metastasis.
Plasminogen activation by uPA occurs at the cell surface where the inactive proenzyme of 
uPA is bound by its cellular receptor uPAR. Pro-uPA is activated by an unknown mechanism 
but remains bound to its receptor (uPAR) where it is capable of activating plasminogen. 
uPA is often secreted, aside from tumor cells, by stromal fibroblasts. In this way, highly 
focalized centers exist where controlled areas of proteolysis can occur at the leading edge 
of the invading cell. The inhibition of receptor bound uPA by plasminogen inhibitors, PAI-1 
and PAI-2, regulates the invasive process and influences the “proteolytic activity map”. The 
potential importance of u-PAR for the development of minimal residual disease in solid 
cancer and its biological relevance for tumor cell dormancy has been described due to its 
influence on the angiogenic switch (16).
The uPA-plasmin system has a  role  in the control of gelatinase (MMP-2, MMP-9) activ-
ity. MMP-2 and MMP-9 are secreted in the form of inactive zymogens that are activated 
extracellularly, a fundamental process for the control of their activity. Both gelatinases 
are associated with the cell surface, binding of uPA and plasminogen to the cell surface 
results in gelatinase activation without the action of other metallo- or acid- proteinases and 
the inhibition of uPA or plasminogen binding to the cell surface blocks gelatinase activa-
tion. Plasmin in soluble phase degrades both gelatinases and gelatinase activation and 
degradation occur in a dose- and time-dependent manner in the presence of physiological 
plasminogen and uPA concentrations. 
MATRIX METALLOPROTEINASES
In tumor progression increased expression and activity of matrix metalloproteinases 
(MMPs) plays a role in angiogenesis, invasion and metastasis. They are a family of zinc 
metalloproteinases, secreted as latent proenzymes, which are activated by proteolytic 
cleavage and are inhibited by the tissue inhibitors of metalloproteinases (TIMPs) (17). There 
are 23 structurally related known members, which differ according to their individual sub-
strate specificities, including stromelysin 1 and 2, gelatinase A and B, matrilysin, neutrophil 
collagenase and interstitial collagenase. Gene encoding stromelysin 3 has been identified 
and is specifically overexpressed in breast carcinomas. The gene was expressed from 
stromal cells in all of the invasive breast carcinoma tested and only in the direct vicinity of 
the neoplastic cells of the tumor. The transformed cells secrete a factor that induces expres-
sion of stromelysin 3 from the stromal fibroblasts and allows progression of the expanding 
tumor cell mass through the ECM into surrounding tissue (18).
MMPs have been subdivided into four subclasses based on their substrate specificity and 
cell localization:
1) Collagenases ( MMP-1 and MMP-8) degrade fibrillar collagen
2) Gelatinases (MMP-2 and MMP-9) have a preference for collagen type IV or denatur-
ated collagen, i.e. gelatin
3) Stromelysins (MMP-3, MMP-7, MMP-10) degrade a wide variety of ECM substrates 
such as proteoglycans, laminin and  fibronectin 
4) Collagenase-3 (MMP-13) has the widest spectrum of substrates 
5) Membrane-type MMPs (MT-1 to MT-6-MMP) integral plasma membrane proteins 
capable of activating MMPs (20).
MMP are secreted as soluble inactive enzymes witch are activated by intrinsic Zn+ ions,
located in the center of the molecule and by extrinsic Ca+ (19). Enzyme activity of MMPs 
is tightly regulated on several levels and dysregulation of MMPs activity can lead to uncon-
trolled degradation of ECM, a process important in tumor metastasis. The most commonly 
associated MMPs with the processes of metastasis are MMP-2 (gelatinase A) and  MMP-9 
(gelatinase B), due to their ability to degrade collagen type IV, a major component of vas-
cular basement membrane (13).
Also, MMPs, specifically MMP-2 and MMP-9, are required for the switch to the angiogenic 
phenotype during tumor progression. MMP-2, unlike MMP-9, is expressed in early human 
breast carcinomas. Increased MMP expression required for the angiogenic switch and may 
predict when a non-angiogenic, microscopic, dormant tumor becomes angiogenic and 
invasive (21,22).
TIMPs are tight binding inhibitors of the active forms of MMPs. There are four of homolo-
gous proteins, referred to as the tissue inhibitors of MMPs (TIMP-1 to TIMP-4) (13). In 
addition to inhibiting matrix metalloproteinase (MMPs) activity, TIMP-2 has been shown ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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to suppress mitogenesis of both host (endothelial, fibroblast) and tumor cells via receptor 
tyrosine kinase (RTK) inactivation. Potent anti-tumor activity of TIMP-2 is composed of 
three separate activities. These are direct inhibition of MMP activity, MMP-independent anti-
angiogenic effects and direct down-regulation of tumor cell EGFR signaling (23).
Membrane-type matrix metalloproteinases (MT-MMP) constitute a subfamily of six distinct 
membrane-associated MMPs. Although the contribution of MT1-MMP during different 
steps of cancer progression has been well documented, the significance of other MT-
MMPs is rather unknown. MT4-MMP overproduction accelerates in vivo tumor growth, 
induces enlargement of blood vessels, and is associated with increased lung metastases.
MT4-MMP is identified as a new putative target to design anticancer strategies (24). 
Activation of proMMP-2 by MT1-MMP is considered a critical event in cancer cell invasion. 
In the activation step, TIMP-2 bound to MT1-MMP on the cell surface acts as a receptor 
for proMMP-2. Subsequently, adjacent TIMP-2-free MT1-MMP activates the proMMP-2 in 
the ternary complex. Tumor size is associated with loss of both MT1-MMP and TIMP-4 
expression suggesting that these two markers could be specific for early stage ductal breast 
carcinomas (25). Physiological activation of MMPs almost certainly involves cleavage by 
plasmin, itself activated at the cell surface by uPA. Therefore, the invading cell, which 
expresses uPAR, can activate an array of proteases at close proximity to a restricted region 
of the cell membrane, which is actively moving through the extracellular matrix.
Degradation of the ECM is clearly a very tightly regulated process, which depends upon 
the relative concentrations of secreted proenzymes, their activators and inhibitors. Tumor 
cells acquire the ability to express motility and invasion-promoting genes and if the ratio of 
LQYDVLRQSURPRWLQJO\WLFHQ]\PHVDFWLYDWRUVH[FHHGVWKDWRILQYDVLRQVXSSUHVVLQJLQKLEL-
tors, at the advancing edge of the tumor, invasion will proceed. It follows that analogues of 
the inhibitors of lytic enzymes known to be secreted by tumor cells may be useful in the 
treatment of tumors by inhibiting the invasion process.
It has recently been shown that overexpression of extracellular matrix metalloproteinase
inducer (EMMPRIN or CD147), a member of the immunoglobulin family and a glycoprotein 
enriched on the surface of tumor cells, promotes invasion, metastasis, and growth and 
survival of malignant cells and confers resistance to some chemotherapeutic drugs (26). 
Tumor-stroma interaction via EMMPRIN regulates, at least in part, the expression pattern 
of MMPs. MMP activity in tumor local environment results in proteolytic cleavage of mem-
brane-associated EMMPRIN, releasing soluble EMMPRIN. Soluble EMMPRIN in turn acts 
in a paracrine fashion on stroma cells that are both adjacent and distant to tumor sites to 
further stimulate the production of MMPs (27).
IMMUNOMODULATION  OF  MATRIX  METALLOPROTEINASE
EXPRESSION
Activation of peripheral blood lymphocytes (PBL) to a locomotive state in order to invade 
target tissue requires production of proteases regulated by cytokines. Matrix metalloprotein-
ases, aside from being involved in the process of angiogenesis and invasion, participate in 
transmigration of lymphocytes to the tumor site. MMP-2 and MMP-9 expression  is modulated
in a cell-type and stimulus-specific manner by a variety of immunological agents such as TGF-
ß, IFN-G, IL-1ß, TNF-A. Effects of IL-12 such as up-regulation of VCAM-1 on the endothelial 
surface, recruits leukocytes to the tumor site, while inhibition of angiogenesis depends on the 
release of TNF-A and IFN-G (28). Experimental models showed that systemic administration 
of IL-12 reduces MMP-9 expression in tumor tissue and that MMP inhibitors increase the 
therapeutic efficacy of IL-12 (29). On the other side, in healthy volunteers, IL-18 mediates 
MMP-9 production in PBL and induces VCAM-1, so MMP-9 production may constitute 
an additional mechanism that contributes to increased metastasis due to IL-18. Cytokines 
(IL-12, IL-18, IL-12 and IL-18 combination), by inducing production of MMP-2 and MMP-9, 
might contribute to PBL migratory ability and support their localization within metastasis. Th1 
cytokines have the most pronounced effect on MMPs production in patients in clinical stage 
II, which suggests better immunomodulating effect of cytokine immunotherapy in improving 
cell mediated antitumor cytotoxicity effect in early stages of breast cancer.
ECM degradation during tissue remodeling requires a proteinase cascade that involves 
plasminogen activators and several MMPs (14, 30, and 31). This proteinase cascade can 
be modulated by specific interactions of both serine proteinases and MMPs with the cell 
surface. The comprehension of the molecular mechanisms that mediate gelatinase–cell 
surface interactions can provide useful tools for the development of novel strategies aimed 
at inhibiting type IV collagenase activity and controlling a variety of tissue remodeling 
processes, including tumor invasion and angiogenesis (13).
Invasion of tumor cells into ECM is an active process that involves four closely related 
processes:
1. Separation of tumor cells from each other
2. Encroachment into local tissues by an active process involving lysis of host cells and 
degradation of the ECM by proteolysis
3. Following separation from each other and degradation of the surrounding stroma, 
tumor cells must then be able to into enter the region cleared by the action of the 
proteolytic enzymes by an active process of cell motility
4. Tumor cells must also promote their own vascularization by  inducing capillary growth 
into and around the tumor
Cyclical repetition of these four steps leads to progressive invasion of tumors. Therefore, 
local invasion by tumor cells allows them to reach a blood or lymph vessel and offers them 
an undesired opportunity to spread to distant body sites. 
METASTASTATIC CASCADE
Although metastasis is the major cause of death in cancer patients, it is well established, 
that metastasis formation is an inefficient process. Studies have demonstrated that late 
events in metastasis formation are largely responsible for the inefficiency of this process. 
The number of circulating tumor cells and tumor emboli correlate with the size and age 
of the primary tumor However, the number of circulating tumor cells does not correlate 
with the clinical outcome of metastases. The inefficiency of tumor cells in completing the 
metastatic cascade is the result of the fact that successful formation of metastatic foci 
consists of several highly complex and interdependent steps. Each step is rate limiting 
in that failure to complete any of these events completely disrupts metastasis formation. 
The steps involved in metastasis formation are thought to be similar in all tumors and are 
characterized as follows:
1. Tumorigenesis. After the initial neoplastic  transformation, the tumor cells undergo 
progressive proliferation that is accompanied by further genetic changes and development 
of a heterogeneous tumor cell population with varying degrees of metastatic potential. The 
initial growth of the primary tumor is supported by the surrounding tissue microenviron-
ment, which eventually becomes rate limiting for further growth.
2. Angiogenic switch. As the tumor grows and central tumor cells become hypoxic, the 
WXPRULQLWLDWHVUHFUXLWPHQWRILWVRZQEORRGVXSSO\E\DSURFHVVFDOOHGWKHßDQJLRJHQLF
VZLWFKßZLWFKLQYROYHVWKHVHFUHWLRQRIYDULRXVDQJLRJHQLFIDFWRUVDQGWKHUHPRYDORUVXS-
pression of angiogenesis inhibitors. 
3. Clonal dominance of  invasive phenotype. Continued genetic alterations in the tumor cell 
population lead to selection of tumor cell clones  with distinct growth advantage and acquisi-
tion of an invasive phenotype. Invasive tumor cells downregulate cell-cell adhesion, alter their 
attachment to the ECM by changing E-cadherin, integrin expression profiles, and by proteolyti-
FDOO\DOWHULQJWKHPDWUL[DFFRPSOLVKVWURPDOLQYDVLRQ7XPRUFHOOVORVHßFRQWDFWLQKLELWLRQßWKDW
prevents normal cells from continuing to divide when they contact their nearest neighbors.
4. Survival of tumor cells and tumor cell emboli in the circulation in vascular or lymphatic 
compartments, despite a variety of hemodynamic and immunologic challenges.
5. Tumor cell arrest in distant organs or lymph nodes. This occurs by size trapping on the 
inflow side of the microcirculation, or by adherence of tumor cells through specific interactions ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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with capillary or lymphatic endothelial cells, or by binding to exposed basement membrane.
6. Extravasation and growth at the secondary site. Arrested tumor cells proliferate in 
response to paracrine growth factors or become dormant. The poor growth of tumor cells 
after extravasation from the circulation is a major factor contributing to the inefficiency of 
the metastatic process.
7. Angiogenesis in metastatic foci. Finally, continued growth of the metastatic foci is also 
dependent on angiogenesis. The development of this neovascular network at the metastatic 
site enhances the metastatic potential of these cells just as it does for the primary tumor.
8. Evasion of immune response. Tumor cell evasion of immune response in metastatic foci 
includes antigenic modulation and immunosuppression  and prevents their eradication.
Therefore, detachment of single cells or clumps of cells from the tumor mass may be 
directly related to a decreased level of cell adhesiveness in tumor populations, regulated by 
a variety of cell surface molecules such as the cadherins and integrins. 
Circulating tumor cells arrest at distant sites and by a repeated process of invasion may 
colonize a secondary site for growth. In some instances, this organ preference of metasta-
sis can be explained simply in terms of the anatomical relationship of the organ with the site 
of primary tumor growth (Ewing theory of metastasis). Some cancers express organ prefer-
ence that is not associated with a non-specific entrapment process, but rather with specific 
determinants, which actively promote the growth of the metastatic cells, thereby providing 
favorable soil (Padgett’s theory of metastasis). Fully metastatic behavior is attributable to 
the expression of only one, or a few, metastasis promoting genes (e.g. CD44) or to the loss 
of an equally small number of metastasis-suppressing genes (e.g. nm23).
After arriving in a secondary site metastatic cells begin proliferating, undergo apoptosis or 
remain as solitary dormant cells. The process of metastasis, although dangerous, is extremely 
inefficient with the majority of the cells undergoing apoptosis and thus becoming clinically irrel-
evant. The cells that begin proliferating and dormant cells are responsible for cancer recurrence 
(21).Tumor dormancy, a complex and still poorly understood phenomenon observed both in 
experimental models and in patients, has been associated with insufficient angiogenic capacity. 
A defined event, termed “angiogenic switch” characterized by an imbalance between pro- and 
anti-angiogenic factors, by the influence of two proteolytic systems, uPAR and MMPs, often 
marks interruption of the dormant state, thus triggering invasive tumor growth (22).
CLINICAL CORRELATION AND PROGNOSIS
There is an urgent need for more efficient prognostic markers that can accurately and reli-
DEO\LGHQWLI\EUHDVWFDUFLQRPDVZLWKSRWHQWLDOWRFDXVHUHFXUUHQFHDQGRUGHDWK7KHUH
are data that show that markers for survival prognosis could be found among the proteins 
that participate or regulate the processes associated with cancer progression. Possible 
candidates include MMPs and their tissue inhibitors, TIMPs.
Due to their specificity for a substrate, i.e. collagen IV, particularly abundant in basal mem-
brane, MMP-2 and MMP-9 are the most involved in tumor initiation, growth and metastasis, 
especially in breast cancer (32). Recently obtained data show increases of the activity of 
MMP-2 and MMP-9 in tumor tissue of breast cancer patients and their correlation with TNM 
clinical stage of the disease (17,18), and significantly higher activity levels in tumor tissue then 
in surrounding tissue (33-35). The analysis of the activity of MMP-2 and MMP-9 in the serum 
of breast cancer patients shows significant clinical stage-dependent increase (36), with high 
level of MMP-9 sera activity being associated with a worse overall survival rate. Novel data 
RI0037,03FRPSOH[DFWLYLW\LQFOLQLFDOVWDJH,9RIWKHGLVHDVHLPSOLFDWHVWKDW003 
overproduction is not balanced by equal amounts of inhibitors. The association of serum 
MMP-2 and MMP-9 activity and clinical stage suggests the usefulness of these parameters 
as markers, both, in the follow up and prognosis of breast cancer patients (36).      
Active estrogen receptors have resulted in tumor progression by stimulating cell growth and 
invasiveness via acceleration of the expression of MMPs, including MMP-9. In addition, a 
tendency of increased MMP-9 expression is found in ER receptor positive patients (37). As 
MMP-9 activation rate increases when lymphovascular permeation occurs, this suggests a 
possible role of MMP-9 in subendothelial basement membrane degradation and intravasa-
tion of cancer cells into vessels (38). 
Aberrant expression of transcription factor activator protein (AP)-2 and HER-2 oncogene 
are related to disease progression and increased invasive capacity in breast cancer 
(39,40),which may be due, in part, to stromal MMP expression and activation caused 
by HER-2 in the early phase of breast cancer (41,42). The reported association of the 
increase in serum MMP-2 and MMP-9 activity and prognostic and therapeutic parameters 
suggests a role of MMP-2 and MMP-9 in prognostic stratification of breast cancer patients. 
This may be helpful in avoiding overtreatment with chemotherapy in the group of lymph 
node-negative patients.  
CONCLUSION
Breast cancer may now be subclassified into luminal, basal, and HER2 subtypes with 
distinct differences in prognosis and response to therapy. Breast tumors that exhibit a 
EDVDOSKHQRW\SHDUHEHOLHYHGWREHVLPLODUWRWKHHDUOLHVWPDPPDU\ßSURJHQLWRUFHOOVßDUH
associated with a poor prognosis and are resistant to standard chemotherapy, supporting 
the hypothesis that therapeutic failure results from inefficient targeting of cancer stem cells 
(43). A recent publication examining the “wound response” signature, which includes 
genes involved in matrix remodeling and angiogenesis, found an association of this signa-
ture with basal-like subtype, suggesting other potential avenues of targeting.
Angiogenesis is a process required not only for embryonic development but is encountered 
in wound healing and in pathological situations, such as tumor growth (44). Molecular 
programs reveal links between wound healing and cancer progression in a variety of com-
mon epithelial tumors. Many of these normally reparative processes may be constitutively 
active in the tumor milieu and critical for tumor engraftment, local invasion, and metastasis 
to distant organs (45,46).
It has been shown that neutralization of VEGF, as well as inhibition of matrix metallopro-
teases (MMPs), using the broad-spectrum MMP inhibitors, both, strongly reduced the 
tumor-induced tube formation. It is suggested that MMPs, in particular MT-MMPs, play a 
pivotal role in the formation of capillary-like tubular structures in a collagen-containing fibrin 
matrix in vitro and, thus, may be involved in angiogenesis in vivo.
Based on the data showing participation of MMPs in breast cancer invasion and metastasis, 
the new concept of “stromal-directed therapy” has been introduced with MMPs as targets 
of MMP inhibitors. The results obtained so far suggest that interrupting “tumor-stroma 
cell communication” by targeting MMPs may provide an alternative therapeutic approach 
for the treatment of invasive breast cancer. However, considering that MMPs, aside from
their up-regulation in pathological processes, have important physiological roles in tissue 
homeostasis, as well as in cell-mediated antitumor immune response, it follows that 
further refining the stromal targets, more specific MMP inhibitors, and preferable testing 
in the bone metastasis setting, represent viable approaches to breast cancer therapy with 
inhibitors of MMP .
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